Therapeutic biology: Checkpoint pathway activation therapy, HIV Tat, and transkingdom RNA interference

Journal of Cellular Physiology

Volumn 209, Issue 3, 2006, Pages 695-700

  Li, Chiang J ^a,b  

^a ARQULE INC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARQ 501; BETA LAPACHONE; CHECKPOINT KINASE 2; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALOPECIA; APOPTOSIS; CANCER CELL; CANCER GENETICS; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE REGULATION; CLINICAL TRIAL; DIARRHEA; DRUG IDENTIFICATION; DRUG TARGETING; GENE SILENCING; GENOME ANALYSIS; GENOME SURVEILLANCE CIRCUITRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; MEDICAL RESEARCH; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RNA INTERFERENCE; SHORT SURVEY; TUMOR CELL; TUMOR XENOGRAFT;

AIDS VACCINES; ANIMALS; GENE PRODUCTS, TAT; GENES, CDC; GENOMICS; HUMANS; LYMPHOCYTE ACTIVATION; NAPHTHOQUINONES; NEOPLASMS; RADIATION-SENSITIZING AGENTS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; THERAPEUTICS;

EID: 33750531435     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20817     Document Type: Short Survey

References (65)

1. Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A, Brander C, Robbins GK, Mazzara GP, Goulder PJ, Walker BD. 2001. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 98:1781-1786.
2. Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE. 2000. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 60:5934-5936.
3. Bartek J, Lukas J. 2003. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429.
4. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864-870.
5. Bekker-Jensen S, Lukas C, Kitagawa R, Melander F, Kastan MB, Bartek J, Lukas J. 2006. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J Cell Biol 173:195-206.
6. Bitko V, Musiyenko A, Shulyayeva O, Barik S. 2005. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11:50-55.
7. Blagosklonny MV. 2003. Cell senescence and hypermitogenic arrest. EMBO Rep 4:358-362.
8. Campisi J. 2005. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120:513-522.
9. Caputo A, Gavioli R, Ensoli B. 2004. Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res 2:357-376.
10. Chabner BA, Roberts TG, Jr. 2005. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 5:65-72.
11. Chen CR, Wang W, Rogoff HA, Li X, Mang W, Li CJ. 2005. Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: Checkpoint activation as a strategy against cancer. Cancer Res 65:6017-6021.
12. Cohen SS, Li C, Ding L, Cao Y, Pardee AB, Shevach EM, Cohen DI. 1999. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. Proc Natl Acad Sci USA 96:10842-10847.
13. Ensoli B. 2006. Hiv-1 tat-based vaccines: From basic science to clinical trials. J Acquir Immune Defic Syndr 42 (Suppl 1):S21-23.
14. Feinberg EH, Hunter CP. 2003. Transport of dsRNA into cells by the transmembrane protein SID-1. Science 301:1545-1547.
15. Folkman J. 2006. Angiogenesis. Annu Rev Med 57:1-18.
16. Gallo RC. 1999. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci USA 96:8324-8326.
17. Gibellini D, Re MC, Ponti C, Celeghini C, Melloni E, La Placa M, Zauli G. 2001. Extracellular Tat activates c-fos promoter in low serum-starved CD4+ T cells. Br J Haematol 112:663-670.
18. Gire V. 2004. Dysfunctional telomeres at senescence signal cell cycle arrest via Chk2. Cell Cycle 3:1217-1220.
19. Goldstein G. 1996. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 2:960-964.
20. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA, Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD. 2005. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434:907-913.
21. Hahn WC, Weinberg RA. 2002. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2:331-341.
22. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW. 2000. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287:1824-1827.
23. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
24. Kastan MB, Bartek J. 2004. Cell-cycle checkpoints and cancer. Nature 432:316-323.
25. Kawabe T. 2004. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3:513-519.
26. Kirschner MW. 2005. The meaning of systems biology. Cell 121:503-504.
27. Li CJ, Averboukh L, Pardee AB. 1993. beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem 268:22463-22468.
28. Li CJ, Friedman DJ, Wang C, Metelev V, Pardee AB. 1995a. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 268:429-431.
29. Li CJ, Wang C, Friedman DJ, Pardee AB. 1995b. Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 92:5461-5464.
30. Li CJ, Wang C, Pardee AB. 1995c. Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Res 55:3712-3715.
31. Li CJ, Ueda Y, Shi B, Borodyansky L, Huang L, Li YZ, Pardee AB. 1997. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci USA 94:8116-8120.
32. Li CJ, Li YZ, Pinto AV, Pardee AB. 1999a. Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: Combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci USA 96:13369-13374.
33. Li YZ, Li CJ, Pinto AV, Pardee AB. 1999b. Release of mitochondrial cytochrome C in both apoptosis and necrosis induced by beta-lapachone in human carcinoma cells. Mol Med 5:232-239.
34. Li Y, Sun X, LaMont JT, Pardee AB, Li CJ. 2003. Selective killing of cancer cells by beta-lapachone: Direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci USA 100:2674-2678.
35. Liu TJ, Lin SY, Chau YP. 2002. Inhibition of poly(ADP-ribose) polymerase activation attenuates beta-lapachone-induced necrotic cell death in human osteosarcoma cells. Toxicol Appl Pharmacol 182:116-125.
36. Lowe SW, Cepero E, Evan G. 2004. Intrinsic tumour suppression. Nature 432:307-315.
37. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. 2000. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 97:10389-10394.
38. McCune JM. 1995. Viral latency in HIV disease. Cell 82:183-188.
39. Melchionna R, Chen XB, Blasina A, McGowan CH. 2000. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat Cell Biol 2:762-765.
40. Nasongkla N, Wiedmann AF, Bruening A, Beman M, Ray D, Bornmann WG, Boothman DA, Gao J. 2003. Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes. Pharm Res 20:1626-1633.
41. Novina CD, Sharp PA. 2004. The RNAi revolution. Nature 430:161-164.
42. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA. 2002. Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 36:617-656.
43. Pardee AB. 2002. Regulation, restriction, and reminiscences. J Biol Chem 277:26709-26716.
44. Pardee AB. 2006. Regulatory molecular biology. Cell Cycle 5:846-852.
45. Planchon SM, Wuerzberger S, Frydman B, Witiak DT, Hutson P, Church DR, Wilding G, Boothman DA. 1995. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res 55:3706-3711.
46. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. 2004. Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene 23:2934-2949.
47. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. 1999. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354:635-639.
48. Roederer M. 1995. T-cell dynamics of immunodeficiency. Nat Med 1:621-622.
49. Schreiber SL. 2005. Small molecules: The missing link in the central dogma. Nat Chem Biol 1:64-66.
50. Schwarz JK, Lovly CM, Piwnica-Worms H. 2003. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol Cancer Res 1:598-609.
51. Shankar P, Manjunath N, Lieberman J. 2005. The prospect of silencing disease using RNA interference. Jama 293:1367-1373.
52. Shapiro GI, Ryan DP, Supko JG, Appleman L, Eder JP, Craig AR, Jones S, Li CJ. 2004. A phase I trial and pharmacokinetic trial ARQ 501, an Activated Checkpoint TherapyTM agent, in patients with advanced solid tumors. Eur J Cancer (Suppl) 2:67.
53. Shapiro GI, Supko JG, Ryan DP, Appelman L, Berkenblit A, Craig AR, Jones S, Yagovane D, Li C, Eder J. 2005. Phase I trial of ARQ 501, an Activated Checkpoint TherapyTM (ACTTM) agent, in patients with advanced solid tumors. JCO 16S, Part I of II (June 1 Supplement):3042.
54. Shapiro GI, Ryan DP, Appleman LJ, Zhu AX, Clark JW, Berkenblit A, Cunningham C, Yagovane D, Dombal G, Li CJ, Eder JP, Supko JG. 2006. Phase I Trial of ARQ 501, a Novel Checkpoint Pathway Activator, in Patients with Advanced Solid Tumors. Proc Am Asso Cancer Res LB 142.
55. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP. 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173-178.
56. Stein GS, Pardee AB. 2004. Cell Cycle and Growth Control: Biomolecular Regulation and Cancer. Hoboken NJ: John Wiley & Sons, Inc.
57. Stockwell BR. 2004. Exploring biology with small organic molecules. Nature 432:846-854.
58. Timmons L, Fire A. 1998. Specific interference by ingested dsRNA. Nature 395:854.
59. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. 2002. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20:142-152.
60. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
61. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, Debatin KM, Krammer PH. 1995. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375:497-500.
62. Xiang S, Fruehauf J, Li CJ. 2006. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol 24:697-702.
63. Yang Y, Fruehauf J, Xiang S, Li CJ. 2006. Genomic instability in precancerous lesions before inactivation of tumor suppressors p53 and APC in patients. Cell Cycle 13:1443-1447.
64. Zhou BB, Bartek J. 2004. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 4:216-225.
65. Zhou BB, Elledge SJ. 2000. The DNA damage response: Putting checkpoints in perspective. Nature 408:433-439.